Growth Metrics

Silence Therapeutics (SLN) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' Income from Continuing Operations rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 24.27%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • Silence Therapeutics' Income from Continuing Operations amounted to -$21.0 million in Q3 2025, which was up 23.38% from -$27.4 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year Income from Continuing Operations high stood at $12.3 million for Q4 2024, and its period low was -$35.5 million during Q3 2024.
  • In the last 3 years, Silence Therapeutics' Income from Continuing Operations had a median value of -$18.6 million in 2023 and averaged -$16.8 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 166.23% in 2024, then crashed by 1,134.00% in 2025.
  • Over the past 5 years, Silence Therapeutics' Income from Continuing Operations (MRQ) stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then fell by 5.23% to -$18.6 million in 2023, then surged by 166.23% to $12.3 million in 2024, then plummeted by 270.36% to -$21.0 million in 2025.
  • Its last three reported values are -$21.0 million in Q3 2025, -$27.4 million for Q2 2025, and -$28.5 million during Q1 2025.